Adverse events related to COVID-19 vaccines: the need for strengthening pharmacovigilance monitoring systems

Sunil Shrestha; Januka Khatri; Sujyoti Shakya; Krisha Danekhu; Asmita Priyadarshini Khatiwada; Ranjit Sah; Bhuvan Kc; Vibhu Paudyal; Saval Khanal; Alfonso J. Rodriguez-morales

doi:10.1007/s40267-021-00852-z

Adverse events related to COVID-19 vaccines: the need for strengthening pharmacovigilance monitoring systems

Sunil Shrestha, Januka Khatri, Sujyoti Shakya, Krisha Danekhu, Asmita Priyadarshini Khatiwada, Ranjit Sah, Bhuvan Kc, Vibhu Paudyal, Saval Khanal, Alfonso J. Rodriguez-morales

Pharmacy

Research output: Contribution to journal › Article › peer-review

59 Downloads (Pure)

Abstract

Coronavirus disease 2019 (COVID-19) is an infectious disease caused by a new species of β-coronavirus genus named severe acute respiratory syndrome coronavirus 2. The COVID-19 pandemic, which started in late 2019 and continues as at mid-2021, has caused enormous damage to health and lives globally. The urgent public health need has led to the development of vaccines against COVID-19 in record-breaking time. The COVID-19 vaccines have been widely rolled out for the masses by many countries following approval for emergency use by the World Health Organization and regulatory agencies in many countries. In addition, several COVID-19 vaccine candidates are undergoing clinical trials. However, myths, fears, rumors, and misconceptions persist, particularly in regard to adverse events. In this commentary, we describe the adverse events associated with COVID-19 vaccines and discuss why it is essential to have a functional adverse event monitoring system in this context.

Original language	English
Pages (from-to)	376–382
Number of pages	7
Journal	Drugs & Therapy Perspectives
Volume	37
Issue number	8
DOIs	https://doi.org/10.1007/s40267-021-00852-z
Publication status	Published - 2 Aug 2021

Bibliographical note

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1007/s40267-021-00852-zLicence: None: All rights reserved

ShresthaS2021Adverse
Shrestha, S., Khatri, J., Shakya, S. et al. Adverse events related to COVID-19 vaccines: the need to strengthen pharmacovigilance monitoring systems. Drugs Ther Perspect 37, 376–382 (2021). https://doi.org/10.1007/s40267-021-00852-z This AAM is subject to Springer Nature reuse terms: https://www.springer.com/gp/open-access/publication-policies/aam-terms-of-use
Accepted author manuscript, 668 KBLicence: Other (please specify with Rights Statement)

https://doi.org/10.1007/s40267-021-00852-zLicence: None: All rights reserved

Cite this

@article{4b2613ddd20b4907bb41fdd78039ffc2,

title = "Adverse events related to COVID-19 vaccines: the need for strengthening pharmacovigilance monitoring systems",

abstract = "Coronavirus disease 2019 (COVID-19) is an infectious disease caused by a new species of β-coronavirus genus named severe acute respiratory syndrome coronavirus 2. The COVID-19 pandemic, which started in late 2019 and continues as at mid-2021, has caused enormous damage to health and lives globally. The urgent public health need has led to the development of vaccines against COVID-19 in record-breaking time. The COVID-19 vaccines have been widely rolled out for the masses by many countries following approval for emergency use by the World Health Organization and regulatory agencies in many countries. In addition, several COVID-19 vaccine candidates are undergoing clinical trials. However, myths, fears, rumors, and misconceptions persist, particularly in regard to adverse events. In this commentary, we describe the adverse events associated with COVID-19 vaccines and discuss why it is essential to have a functional adverse event monitoring system in this context. ",

author = "Sunil Shrestha and Januka Khatri and Sujyoti Shakya and Krisha Danekhu and Khatiwada, {Asmita Priyadarshini} and Ranjit Sah and Bhuvan Kc and Vibhu Paudyal and Saval Khanal and Rodriguez-morales, {Alfonso J.}",

note = "Copyright {\textcopyright} 2021, The Author(s), under exclusive licence to Springer Nature Switzerland AG",

year = "2021",

month = aug,

day = "2",

doi = "10.1007/s40267-021-00852-z",

language = "English",

volume = "37",

pages = "376–382",

journal = "Drugs & Therapy Perspectives",

issn = "1172-0360",

publisher = "Springer",

number = "8",

}

TY - JOUR

T1 - Adverse events related to COVID-19 vaccines

T2 - the need for strengthening pharmacovigilance monitoring systems

AU - Shrestha, Sunil

AU - Khatri, Januka

AU - Shakya, Sujyoti

AU - Danekhu, Krisha

AU - Khatiwada, Asmita Priyadarshini

AU - Sah, Ranjit

AU - Kc, Bhuvan

AU - Paudyal, Vibhu

AU - Khanal, Saval

AU - Rodriguez-morales, Alfonso J.

PY - 2021/8/2

Y1 - 2021/8/2

N2 - Coronavirus disease 2019 (COVID-19) is an infectious disease caused by a new species of β-coronavirus genus named severe acute respiratory syndrome coronavirus 2. The COVID-19 pandemic, which started in late 2019 and continues as at mid-2021, has caused enormous damage to health and lives globally. The urgent public health need has led to the development of vaccines against COVID-19 in record-breaking time. The COVID-19 vaccines have been widely rolled out for the masses by many countries following approval for emergency use by the World Health Organization and regulatory agencies in many countries. In addition, several COVID-19 vaccine candidates are undergoing clinical trials. However, myths, fears, rumors, and misconceptions persist, particularly in regard to adverse events. In this commentary, we describe the adverse events associated with COVID-19 vaccines and discuss why it is essential to have a functional adverse event monitoring system in this context.

AB - Coronavirus disease 2019 (COVID-19) is an infectious disease caused by a new species of β-coronavirus genus named severe acute respiratory syndrome coronavirus 2. The COVID-19 pandemic, which started in late 2019 and continues as at mid-2021, has caused enormous damage to health and lives globally. The urgent public health need has led to the development of vaccines against COVID-19 in record-breaking time. The COVID-19 vaccines have been widely rolled out for the masses by many countries following approval for emergency use by the World Health Organization and regulatory agencies in many countries. In addition, several COVID-19 vaccine candidates are undergoing clinical trials. However, myths, fears, rumors, and misconceptions persist, particularly in regard to adverse events. In this commentary, we describe the adverse events associated with COVID-19 vaccines and discuss why it is essential to have a functional adverse event monitoring system in this context.

UR - http://www.scopus.com/inward/record.url?scp=85111895141&partnerID=8YFLogxK

U2 - 10.1007/s40267-021-00852-z

DO - 10.1007/s40267-021-00852-z

M3 - Article

SN - 1172-0360

VL - 37

SP - 376

EP - 382

JO - Drugs & Therapy Perspectives

JF - Drugs & Therapy Perspectives

IS - 8

ER -

Adverse events related to COVID-19 vaccines: the need for strengthening pharmacovigilance monitoring systems

Abstract

Bibliographical note

UN SDGs

Access to Document

Fingerprint

Cite this